Content: Slate Blackcurrant Watermelon Strawberry Orange Banana Apple Emerald Chocolate Marble
Background: Slate Blackcurrant Watermelon Strawberry Orange Banana Apple Emerald Chocolate Marble
Pattern: Blank Waves Notes Sharp Wood Rockface Leather Honey Vertical Triangles
Sign in to follow this  
Health Reporter

Pubmed-Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation.

1 post in this topic

Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation.

Clin Gastroenterol Hepatol. 2018 Apr 11;:

Authors: Ballou S, Beath A, Kaptchuk TJ, Hirsch W, Sommers T, Nee J, Iturrino J, Rangan V, Singh P, Jones M, Lembo A

Abstract
BACKGROUND & AIMS: A high proportion of patients with irritable bowel syndrome (IBS) respond to placebo in clinical trials (estimated at about 40%). We aimed to identify factors that contribute to the high placebo response rate using data from a placebo-controlled trials of patients with IBS.
METHODS: We performed a retrospective analysis of 599 women with IBS with constipation who were in the placebo group of a 12-week, randomized, double-blind, phase 3 trial of the experimental medication renzapride. Primary analyses evaluated frequency of abdominal pain in patients who received placebo, defined as ≥ 30% pain improvement from baseline for ≥6 of the 12 study weeks. We performed backward elimination regression with bootstrapping to identify factors associated with response to placebo.
RESULTS: In the placebo group, 29.0% of the patients had an abdominal pain response. Factors associated with a response to placebo were baseline variation in abdominal pain (odds ratio [OR], 1.71), maximum baseline pain severity (OR, 1.34), and placebo response in study week 2 (OR, 2.23) or week 3 (OR, 3.69). Factors associated with lack of response to placebo were number of baseline complete spontaneous bowel movements (OR, 0.73; P=.019) and final baseline pain ratings (OR, 0.73; P<.001).
CONCLUSION: We identified factors associated with a response in abdominal pain to placebo using original data from an IBS clinical trial. Baseline factors associated with the placebo response in women with IBS and constipation include variation in baseline pain symptoms, severity of baseline symptoms, and early improvement of abdominal pain. These findings have significant implications for clinical trial design.

PMID: 29654913 [PubMed - as supplied by publisher]

View the full article

Share this post


Link to post
Share on other sites
Advertisement
Sign in to follow this